Abstract
Susceptibility to chronic obstructive pulmonary disease (COPD) beyond cigarette smoking is incompletely understood, although several genetic variants associated with COPD are known to regulate airway branch development. We demonstrate that in vivo central airway branch variants are present in 26.5% of the general population, are unchanged over 10 y, and exhibit strong familial aggregation. The most common airway branch variant is associated with COPD in two cohorts (n = 5,054), with greater central airway bifurcation density, and with emphysema throughout the lung. The second most common airway branch variant is associated with COPD among smokers, with narrower airway lumens in all lobes, and with genetic polymorphisms within the FGF10 gene. We conclude that central airway branch variation, readily detected by computed tomography, is a biomarker of widely altered lung structure with a genetic basis and represents a COPD susceptibility factor.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E974-E981 |
| Journal | Proceedings of the National Academy of Sciences of the United States of America |
| Volume | 115 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jan 30 2018 |
| Externally published | Yes |
Keywords
- Airway branching
- Chronic obstructive pulmonary disease
- Computed tomography
- Fibroblast growth factor
ASJC Scopus subject areas
- General
Fingerprint
Dive into the research topics of 'Human airway branch variation and chronic obstructive pulmonary disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 5, 30.01.2018, p. E974-E981.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Human airway branch variation and chronic obstructive pulmonary disease
AU - the MESA Lung and SPIROMICS investigators
AU - Smith, Benjamin M.
AU - Traboulsi, Hussein
AU - Austin, John H.M.
AU - Manichaikul, Ani
AU - Hoffman, Eric A.
AU - Bleecker, Eugene R.
AU - Cardoso, Wellington V.
AU - Cooper, Christopher
AU - Couper, David J.
AU - Dashnaw, Stephen M.
AU - Guo, Jia
AU - Han, Mei Lan K.
AU - Hansel, Nadia N.
AU - Hughes, Emlyn W.
AU - Jacobs, David R.
AU - Kanner, Richard E.
AU - Kaufman, Joel D.
AU - Kleerup, Eric
AU - Lin, Ching Long
AU - Liu, Kiang
AU - Lo Cascio, Christian M.
AU - Martinez, Fernando J.
AU - Nguyen, Jennifer N.
AU - Prince, Martin R.
AU - Rennard, Stephen
AU - Rich, Stephen S.
AU - Simon, Leora
AU - Sun, Yanping
AU - Watson, Karol E.
AU - Woodruff, Prescott G.
AU - Baglole, Carolyn J.
AU - Barr, R. Graham
N1 - Funding Information: We thank the other investigators, the staff, and the participants of the MESA Lung Study and SPIROMICS for their valuable contributions (a full list of participating MESA investigators and institutions can be found at https://www.mesa-nhlbi.org; more information about the study and how to access SPIROMICS data is available at www.spiromics.org) and acknowledge the following current and former investigators of the SPIROMICS sites and reading centers: Neil E. Alexis, PhD; Wayne H. Anderson, PhD; Richard C. Boucher, MD; Russell P. Bowler, MD, PhD; Elizabeth E. Carretta, MPH; Stephanie A. Christenson, MD; Alejandro P. Comellas, MD; Gerard J. Criner, MD; Ronald G. Crystal, MD; Jeffrey L. Curtis, MD; Claire M. Doerschuk, MD; Mark T. Dransfield, MD; Christine M. Freeman, PhD; Annette T. Hastie, PhD; Jerry A. Krishnan, MD, PhD; Lisa M. LaVange, PhD; Stephen C. Lazarus, MD; Deborah A. Meyers, PhD; John D. Newell, Jr, MD; Elizabeth C. Oelsner, MD, MPH; Wanda K. O’Neal, PhD; Robert Paine, III, MD; Nirupama Putcha, MD, MHS; Donald P. Tashkin, MD; Mary Beth Scholand, MD; J. Michael Wells, MD; and Robert A. Wise, MD. The project officers from the Lung Division of the National Heart, Lung, and Blood Institute (NHLBI) were Lisa Postow, PhD, Thomas Croxton, PhD, MD, and Antonello Punturieri, MD, PhD. SPIROMICS was supported by NIH/NHLBI Contracts HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C HHSN268200900019C, and HHSN268200900020C, which were supplemented by contributions made through the Foundation for the NIH and COPD Foundation from AstraZeneca, Bellerophon Pharmaceuticals, Boehringer-Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici SpA, Forest Research Institute, Inc., GlaxoSmithKline, Grifols Therapeutics, Inc., Ikaria, Inc., Nycomed GmbH, Takeda Pharmaceutical Company, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi. Financial support was provided by NIH/NHLBI Grants R01-HL130506, R01-HL077612, R01-HL093081, R01-HL112986, RC1HL100543, RD831697, N01-HC-95159, N01-HC-95160, N01-HC-95169, N01-HC-95162, N01-HC-95164, U01-HL114494, N01-HC95159-HC95169, the NIH/NHLBI contracts named above, the McGill University Health Center Research Institute, and the Fonds de la recherche en santé Québec (Quebec Health Research Fund). Funding Information: ACKNOWLEDGMENTS. We thank the other investigators, the staff, and the participants of the MESA Lung Study and SPIROMICS for their valuable contributions (a full list of participating MESA investigators and institutions can be found at https://www.mesa-nhlbi.org; more information about the study and how to access SPIROMICS data is available at www.spiromics.org) and acknowledge the following current and former investigators of the SPIROMICS sites and reading centers: Neil E. Alexis, PhD; Wayne H. Anderson, PhD; Richard C. Boucher, MD; Russell P. Bowler, MD, PhD; Elizabeth E. Carretta, MPH; Stephanie A. Christenson, MD; Alejandro P. Comellas, MD; Gerard J. Criner, MD; Ronald G. Crystal, MD; Jeffrey L. Curtis, MD; Claire M. Doerschuk, MD; Mark T. Dransfield, MD; Christine M. Freeman, PhD; Annette T. Hastie, PhD; Jerry A. Krishnan, MD, PhD; Lisa M. LaVange, PhD; Stephen C. Lazarus, MD; Deborah A. Meyers, PhD; John D. Newell, Jr, MD; Elizabeth C. Oelsner, MD, MPH; Wanda K. O’Neal, PhD; Robert Paine, III, MD; Nirupama Putcha, MD, MHS; Donald P. Tashkin, MD; Mary Beth Scholand, MD; J. Michael Wells, MD; and Robert A. Wise, MD. The project officers from the Lung Division of the National Heart, Lung, and Blood Institute (NHLBI) were Lisa Postow, PhD, Thomas Croxton, PhD, MD, and Antonello Punturieri, MD, PhD. SPIROMICS was supported by NIH/NHLBI Contracts HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C HHSN268200900019C, and HHSN268200900020C, which were supplemented by contributions made through the Foundation for the NIH and COPD Foundation from AstraZeneca, Bellerophon Pharmaceuticals, Boehringer-Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici SpA, Forest Research Institute, Inc., GlaxoSmithKline, Grifols Therapeutics, Inc., Ikaria, Inc., Nycomed GmbH, Takeda Pharmaceutical Company, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi. Financial support was provided by NIH/NHLBI Grants R01-HL130506, R01-HL077612, R01-HL093081, R01-HL112986, RC1HL100543, RD831697, N01-HC-95159, N01-HC-95160, N01-HC-95169, N01-HC-95162, N01-HC-95164, U01-HL114494, N01-HC95159-HC95169, the NIH/NHLBI contracts named above, the McGill University Health Center Research Institute, and the Fonds de la recherche en santé Québec (Quebec Health Research Fund).
PY - 2018/1/30
Y1 - 2018/1/30
N2 - Susceptibility to chronic obstructive pulmonary disease (COPD) beyond cigarette smoking is incompletely understood, although several genetic variants associated with COPD are known to regulate airway branch development. We demonstrate that in vivo central airway branch variants are present in 26.5% of the general population, are unchanged over 10 y, and exhibit strong familial aggregation. The most common airway branch variant is associated with COPD in two cohorts (n = 5,054), with greater central airway bifurcation density, and with emphysema throughout the lung. The second most common airway branch variant is associated with COPD among smokers, with narrower airway lumens in all lobes, and with genetic polymorphisms within the FGF10 gene. We conclude that central airway branch variation, readily detected by computed tomography, is a biomarker of widely altered lung structure with a genetic basis and represents a COPD susceptibility factor.
AB - Susceptibility to chronic obstructive pulmonary disease (COPD) beyond cigarette smoking is incompletely understood, although several genetic variants associated with COPD are known to regulate airway branch development. We demonstrate that in vivo central airway branch variants are present in 26.5% of the general population, are unchanged over 10 y, and exhibit strong familial aggregation. The most common airway branch variant is associated with COPD in two cohorts (n = 5,054), with greater central airway bifurcation density, and with emphysema throughout the lung. The second most common airway branch variant is associated with COPD among smokers, with narrower airway lumens in all lobes, and with genetic polymorphisms within the FGF10 gene. We conclude that central airway branch variation, readily detected by computed tomography, is a biomarker of widely altered lung structure with a genetic basis and represents a COPD susceptibility factor.
KW - Airway branching
KW - Chronic obstructive pulmonary disease
KW - Computed tomography
KW - Fibroblast growth factor
UR - http://www.scopus.com/inward/record.url?scp=85041228991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041228991&partnerID=8YFLogxK
U2 - 10.1073/pnas.1715564115
DO - 10.1073/pnas.1715564115
M3 - Article
C2 - 29339516
AN - SCOPUS:85041228991
SN - 0027-8424
VL - 115
SP - E974-E981
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 5
ER -